pyruvic acid and Anemia, Sickle Cell

pyruvic acid has been researched along with Anemia, Sickle Cell in 3 studies

Pyruvic Acid: An intermediate compound in the metabolism of carbohydrates, proteins, and fats. In thiamine deficiency, its oxidation is retarded and it accumulates in the tissues, especially in nervous structures. (From Stedman, 26th ed)
pyruvic acid : A 2-oxo monocarboxylic acid that is the 2-keto derivative of propionic acid. It is a metabolite obtained during glycolysis.

Anemia, Sickle Cell: A disease characterized by chronic hemolytic anemia, episodic painful crises, and pathologic involvement of many organs. It is the clinical expression of homozygosity for hemoglobin S.

Research

Studies (3)

Authors

Clinical Trials (1)

Trial Overview

Trial Outcomes

Number Participants With Increase of ≥ 1 g/dL in Hemoglobin

To assess the clinical safety and tolerability of multiple escalating doses of AG-348, an allosteric activator of the enzyme pyruvate kinase, in subjects with stable sickle cell disease (SCD). Safety and tolerability were assessed by defined as a ≥ 1 g/dL increase in hemoglobin at any dose level compared to baseline. (NCT04000165)
Timeframe: 14 weeks

Number Participants With Serious Adverse Events That Were Possibly Drug-related Serious Adverse Events

To assess the clinical safety and tolerability of multiple escalating doses of AG-348, an allosteric activator of the enzyme pyruvate kinase, in subjects with stable sickle cell disease (SCD). Safety and tolerability were assessed by frequency and severity of adverse events (AEs) using Common Terminology Criteria for Adverse Events (CTCAE) 5.0. (NCT04000165)
Timeframe: 14 weeks

Change in Absolute Reticulocyte Count at Each Dose Level of AG-348

To assess change in absolute reticulocyte count in stable sickle cell disease participants at each dose level of AG-348 (NCT04000165)
Timeframe: 14 weeks

Change in Aspartate Aminotransferase (AST) at Each Dose Level of AG-348

To assess change in aspartate aminotransferase (AST) in stable sickle cell disease participants at each dose level of AG-348 (NCT04000165)
Timeframe: 14 weeks

Change in Fetal Hemoglobin at Each Dose Level of AG-348

To assess the change in fetal hemoglobin (HbF) in stable sickle cell disease participants at each dose level of AG-348 (NCT04000165)
Timeframe: 14 weeks

Change in Hemoglobin at Each Dose Level of AG-348

To assess change in hemoglobin in stable sickle cell disease participants at each dose level of AG-348 (NCT04000165)
Timeframe: 14 weeks

Change in Lactic Acid Dehydrogenase (LDH) at Each Dose Level of AG-348

To assess change in lactic acid dehydrogenase (LDH) in stable sickle cell disease participants at each dose level of AG-348 (NCT04000165)
Timeframe: 14 weeks

Change in Mean Corpuscular Volume (MCV) at Each Dose Level of AG-348

To assess change in mean corpuscular volume (MCV) in stable sickle cell disease participants at each dose level of AG-348 (NCT04000165)
Timeframe: 14 weeks

Change in Total Bilirubin at Each Dose Level of AG-348

To assess change in total bilirubin in stable sickle cell disease participants at each dose level of AG-348 (NCT04000165)
Timeframe: 14 weeks

Number Participants With Most Common Reported Drug Related Adverse Events

To assess the clinical safety and tolerability of multiple escalating doses of AG-348, an allosteric activator of the enzyme pyruvate kinase, in subjects with stable sickle cell disease (SCD). Safety and tolerability were assessed by frequency and severity of adverse events (AEs) using Common Terminology Criteria for Adverse Events (CTCAE) 5.0. (NCT04000165)
Timeframe: 14 weeks

Percent Change From Baseline in Oxygen Binding p50 Value at Each Dose Level of AG-348

Measure percent change from baseline in oxygen binding p50 value at each dose level of AG-348 (NCT04000165)
Timeframe: 14 weeks

Percent Change From Baseline of 2,3-DPG at Each Dose Level of AG-348

To understand the mechanisms of action of AG- 348 on the glycolytic pathway in sickle cell disease through laboratory studies of specific pharmacodynamics of 2,3-DPG at each dose level of AG-348. (NCT04000165)
Timeframe: 14 weeks

Percent Change From Baseline of Adenosine Triphosphate (ATP) at Each Dose Level of AG-348

To understand the mechanisms of action of AG- 348 on the glycolytic pathway in sickle cell disease through laboratory studies of specific pharmacodynamics of adenosine triphosphate (ATP) at each dose level of AG-348. (NCT04000165)
Timeframe: 14 weeks

Percent Change in Time (Mins) at Which 50% of Red Blood Cells Are Sickled (t50) Value at Each Dose Level of AG-348

Measure percent change in Time (mins) at which 50% of red blood cells are sickled (t50) Value at Each Dose Level of AG-348 (NCT04000165)
Timeframe: 14 weeks

Percent Change of PK-R at Each Dose Level of AG-348

To understand the mechanisms of action of AG- 348 on the glycolytic pathway in sickle cell disease through laboratory studies of specific pharmacodynamics of PK-R at each dose level of AG-348. (NCT04000165)
Timeframe: 14 weeks

Trials

1 trial available for pyruvic acid and Anemia, Sickle Cell

Other Studies

2 other studies available for pyruvic acid and Anemia, Sickle Cell